Treatment of metastatic prostate carcinoma with the depot LRH analog zoladex
A long‐acting LRH agonist (ICI 118630, Zoladex) was given by monthly subcutaneous injection to 25 patients with previously untreated symptomatic advanced prostatic carcinoma. The medication was well tolerated with the only side effect being hot flushes in 15 patients. Subjective improvement occurred...
Gespeichert in:
| Veröffentlicht in: | The Prostate 1988, Vol.12 (2), p.119-127 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 127 |
|---|---|
| container_issue | 2 |
| container_start_page | 119 |
| container_title | The Prostate |
| container_volume | 12 |
| creator | Holdaway, I. M. Ibbertson, H. K. Croxson, M. S. Harvey, V. Boulton, J. List, A. Rutland, M. Knox, B. S. |
| description | A long‐acting LRH agonist (ICI 118630, Zoladex) was given by monthly subcutaneous injection to 25 patients with previously untreated symptomatic advanced prostatic carcinoma. The medication was well tolerated with the only side effect being hot flushes in 15 patients. Subjective improvement occurred in 22 patients, and disease remission or stabilization judged by objective criteria was seen in 21 and 18 patients from the total group at 3 and 6 months of treatment, respectively. Twelve of 18 patients followed for 1 year were still in objective remission/stabilization. Prostate volume measured by ultrasound decreased by a mean value of 75% and urine flow increased significantly. There were significant falls in serum testosterone and gonadotrophin levels and significant although lesser reductions in serum androstenedione and dehydroepiandrosterone. These changes were accompanied by significant reductions in serum acid and alkaline phosphatase and a rise in serum osteocalcin. Four patients (16%) experienced an initial tumor flare. Although only a small number of patients were studied, Zoladex appeared to be a well‐tolerated agent for treatment of prostatic carcinoma, with an initial clinical response similar to that seen with standard endocrine therapy. |
| doi_str_mv | 10.1002/pros.2990120203 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_78224337</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>78224337</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4113-1c60aca4124b4cbd24907b48e0471715ded5c16981d0ea921fa67e077935b4fe3</originalsourceid><addsrcrecordid>eNqFkM1vEzEQxS0EKiFw5oTkA-K27YztXcfihCLaUoUWlSKO1qx3li7sR7p21Ja_no0SBXHi4rE0v_dm5gnxGuEYAdTJehzisXIOUIEC_UTMEJzNAEz-VMxAWcgMavtcvIjxJ8CkAXUkjpQrCqdxJlY3I1PquE9yqGXHiWKi1AS5NZ5-LAONoemHjuR9k25lumVZ8XpIcnV9Lqmndvghfw8tVfzwUjyrqY38al_n4tvpx5vleba6Ovu0_LDKgkHUGYYCKJBBZUoTykoZB7Y0CwZj0WJecZUHLNwCK2ByCmsqLIO1TuelqVnPxbud77Tk3YZj8l0TA7ct9TxsorcLpYzWdgJPdmCYrokj1349Nh2Njx7Bb_Pz2zP93_wmxZu99absuDrw-8Cm_tt9n2Kgth6pD008YFZpZadnLt7vsPum5cf_TfVfrq--_rNEtlM3MfHDQU3jL19YbXP__fLMny4uLpcXn9Fb_QfqWZij</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>78224337</pqid></control><display><type>article</type><title>Treatment of metastatic prostate carcinoma with the depot LRH analog zoladex</title><source>MEDLINE</source><source>Access via Wiley Online Library</source><creator>Holdaway, I. M. ; Ibbertson, H. K. ; Croxson, M. S. ; Harvey, V. ; Boulton, J. ; List, A. ; Rutland, M. ; Knox, B. S.</creator><creatorcontrib>Holdaway, I. M. ; Ibbertson, H. K. ; Croxson, M. S. ; Harvey, V. ; Boulton, J. ; List, A. ; Rutland, M. ; Knox, B. S.</creatorcontrib><description>A long‐acting LRH agonist (ICI 118630, Zoladex) was given by monthly subcutaneous injection to 25 patients with previously untreated symptomatic advanced prostatic carcinoma. The medication was well tolerated with the only side effect being hot flushes in 15 patients. Subjective improvement occurred in 22 patients, and disease remission or stabilization judged by objective criteria was seen in 21 and 18 patients from the total group at 3 and 6 months of treatment, respectively. Twelve of 18 patients followed for 1 year were still in objective remission/stabilization. Prostate volume measured by ultrasound decreased by a mean value of 75% and urine flow increased significantly. There were significant falls in serum testosterone and gonadotrophin levels and significant although lesser reductions in serum androstenedione and dehydroepiandrosterone. These changes were accompanied by significant reductions in serum acid and alkaline phosphatase and a rise in serum osteocalcin. Four patients (16%) experienced an initial tumor flare. Although only a small number of patients were studied, Zoladex appeared to be a well‐tolerated agent for treatment of prostatic carcinoma, with an initial clinical response similar to that seen with standard endocrine therapy.</description><identifier>ISSN: 0270-4137</identifier><identifier>EISSN: 1097-0045</identifier><identifier>DOI: 10.1002/pros.2990120203</identifier><identifier>PMID: 2966931</identifier><identifier>CODEN: PRSTDS</identifier><language>eng</language><publisher>New York: Wiley Subscription Services, Inc., A Wiley Company</publisher><subject>Adult ; Aged ; Aged, 80 and over ; androstenedione ; Antineoplastic agents ; Biological and medical sciences ; Buserelin - adverse effects ; Buserelin - analogs & derivatives ; Buserelin - therapeutic use ; Chemotherapy ; dehydroepiandrosterone ; Delayed-Action Preparations ; Gonadal Steroid Hormones - blood ; Gonadotropin-Releasing Hormone - analogs & derivatives ; Goserelin ; Humans ; Male ; Medical sciences ; Middle Aged ; osteocalcin ; Pain - drug therapy ; Pharmacology. Drug treatments ; Prostatic Neoplasms - drug therapy ; Prostatic Neoplasms - secondary ; Ultrasonography</subject><ispartof>The Prostate, 1988, Vol.12 (2), p.119-127</ispartof><rights>Copyright © 1988 Wiley‐Liss, Inc., A Wiley Company</rights><rights>1989 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4113-1c60aca4124b4cbd24907b48e0471715ded5c16981d0ea921fa67e077935b4fe3</citedby><cites>FETCH-LOGICAL-c4113-1c60aca4124b4cbd24907b48e0471715ded5c16981d0ea921fa67e077935b4fe3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fpros.2990120203$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fpros.2990120203$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,4024,27923,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=7232772$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/2966931$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Holdaway, I. M.</creatorcontrib><creatorcontrib>Ibbertson, H. K.</creatorcontrib><creatorcontrib>Croxson, M. S.</creatorcontrib><creatorcontrib>Harvey, V.</creatorcontrib><creatorcontrib>Boulton, J.</creatorcontrib><creatorcontrib>List, A.</creatorcontrib><creatorcontrib>Rutland, M.</creatorcontrib><creatorcontrib>Knox, B. S.</creatorcontrib><title>Treatment of metastatic prostate carcinoma with the depot LRH analog zoladex</title><title>The Prostate</title><addtitle>Prostate</addtitle><description>A long‐acting LRH agonist (ICI 118630, Zoladex) was given by monthly subcutaneous injection to 25 patients with previously untreated symptomatic advanced prostatic carcinoma. The medication was well tolerated with the only side effect being hot flushes in 15 patients. Subjective improvement occurred in 22 patients, and disease remission or stabilization judged by objective criteria was seen in 21 and 18 patients from the total group at 3 and 6 months of treatment, respectively. Twelve of 18 patients followed for 1 year were still in objective remission/stabilization. Prostate volume measured by ultrasound decreased by a mean value of 75% and urine flow increased significantly. There were significant falls in serum testosterone and gonadotrophin levels and significant although lesser reductions in serum androstenedione and dehydroepiandrosterone. These changes were accompanied by significant reductions in serum acid and alkaline phosphatase and a rise in serum osteocalcin. Four patients (16%) experienced an initial tumor flare. Although only a small number of patients were studied, Zoladex appeared to be a well‐tolerated agent for treatment of prostatic carcinoma, with an initial clinical response similar to that seen with standard endocrine therapy.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>androstenedione</subject><subject>Antineoplastic agents</subject><subject>Biological and medical sciences</subject><subject>Buserelin - adverse effects</subject><subject>Buserelin - analogs & derivatives</subject><subject>Buserelin - therapeutic use</subject><subject>Chemotherapy</subject><subject>dehydroepiandrosterone</subject><subject>Delayed-Action Preparations</subject><subject>Gonadal Steroid Hormones - blood</subject><subject>Gonadotropin-Releasing Hormone - analogs & derivatives</subject><subject>Goserelin</subject><subject>Humans</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>osteocalcin</subject><subject>Pain - drug therapy</subject><subject>Pharmacology. Drug treatments</subject><subject>Prostatic Neoplasms - drug therapy</subject><subject>Prostatic Neoplasms - secondary</subject><subject>Ultrasonography</subject><issn>0270-4137</issn><issn>1097-0045</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1988</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkM1vEzEQxS0EKiFw5oTkA-K27YztXcfihCLaUoUWlSKO1qx3li7sR7p21Ja_no0SBXHi4rE0v_dm5gnxGuEYAdTJehzisXIOUIEC_UTMEJzNAEz-VMxAWcgMavtcvIjxJ8CkAXUkjpQrCqdxJlY3I1PquE9yqGXHiWKi1AS5NZ5-LAONoemHjuR9k25lumVZ8XpIcnV9Lqmndvghfw8tVfzwUjyrqY38al_n4tvpx5vleba6Ovu0_LDKgkHUGYYCKJBBZUoTykoZB7Y0CwZj0WJecZUHLNwCK2ByCmsqLIO1TuelqVnPxbud77Tk3YZj8l0TA7ct9TxsorcLpYzWdgJPdmCYrokj1349Nh2Njx7Bb_Pz2zP93_wmxZu99absuDrw-8Cm_tt9n2Kgth6pD008YFZpZadnLt7vsPum5cf_TfVfrq--_rNEtlM3MfHDQU3jL19YbXP__fLMny4uLpcXn9Fb_QfqWZij</recordid><startdate>1988</startdate><enddate>1988</enddate><creator>Holdaway, I. M.</creator><creator>Ibbertson, H. K.</creator><creator>Croxson, M. S.</creator><creator>Harvey, V.</creator><creator>Boulton, J.</creator><creator>List, A.</creator><creator>Rutland, M.</creator><creator>Knox, B. S.</creator><general>Wiley Subscription Services, Inc., A Wiley Company</general><general>Wiley-Liss</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>1988</creationdate><title>Treatment of metastatic prostate carcinoma with the depot LRH analog zoladex</title><author>Holdaway, I. M. ; Ibbertson, H. K. ; Croxson, M. S. ; Harvey, V. ; Boulton, J. ; List, A. ; Rutland, M. ; Knox, B. S.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4113-1c60aca4124b4cbd24907b48e0471715ded5c16981d0ea921fa67e077935b4fe3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1988</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>androstenedione</topic><topic>Antineoplastic agents</topic><topic>Biological and medical sciences</topic><topic>Buserelin - adverse effects</topic><topic>Buserelin - analogs & derivatives</topic><topic>Buserelin - therapeutic use</topic><topic>Chemotherapy</topic><topic>dehydroepiandrosterone</topic><topic>Delayed-Action Preparations</topic><topic>Gonadal Steroid Hormones - blood</topic><topic>Gonadotropin-Releasing Hormone - analogs & derivatives</topic><topic>Goserelin</topic><topic>Humans</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>osteocalcin</topic><topic>Pain - drug therapy</topic><topic>Pharmacology. Drug treatments</topic><topic>Prostatic Neoplasms - drug therapy</topic><topic>Prostatic Neoplasms - secondary</topic><topic>Ultrasonography</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Holdaway, I. M.</creatorcontrib><creatorcontrib>Ibbertson, H. K.</creatorcontrib><creatorcontrib>Croxson, M. S.</creatorcontrib><creatorcontrib>Harvey, V.</creatorcontrib><creatorcontrib>Boulton, J.</creatorcontrib><creatorcontrib>List, A.</creatorcontrib><creatorcontrib>Rutland, M.</creatorcontrib><creatorcontrib>Knox, B. S.</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>The Prostate</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Holdaway, I. M.</au><au>Ibbertson, H. K.</au><au>Croxson, M. S.</au><au>Harvey, V.</au><au>Boulton, J.</au><au>List, A.</au><au>Rutland, M.</au><au>Knox, B. S.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Treatment of metastatic prostate carcinoma with the depot LRH analog zoladex</atitle><jtitle>The Prostate</jtitle><addtitle>Prostate</addtitle><date>1988</date><risdate>1988</risdate><volume>12</volume><issue>2</issue><spage>119</spage><epage>127</epage><pages>119-127</pages><issn>0270-4137</issn><eissn>1097-0045</eissn><coden>PRSTDS</coden><abstract>A long‐acting LRH agonist (ICI 118630, Zoladex) was given by monthly subcutaneous injection to 25 patients with previously untreated symptomatic advanced prostatic carcinoma. The medication was well tolerated with the only side effect being hot flushes in 15 patients. Subjective improvement occurred in 22 patients, and disease remission or stabilization judged by objective criteria was seen in 21 and 18 patients from the total group at 3 and 6 months of treatment, respectively. Twelve of 18 patients followed for 1 year were still in objective remission/stabilization. Prostate volume measured by ultrasound decreased by a mean value of 75% and urine flow increased significantly. There were significant falls in serum testosterone and gonadotrophin levels and significant although lesser reductions in serum androstenedione and dehydroepiandrosterone. These changes were accompanied by significant reductions in serum acid and alkaline phosphatase and a rise in serum osteocalcin. Four patients (16%) experienced an initial tumor flare. Although only a small number of patients were studied, Zoladex appeared to be a well‐tolerated agent for treatment of prostatic carcinoma, with an initial clinical response similar to that seen with standard endocrine therapy.</abstract><cop>New York</cop><pub>Wiley Subscription Services, Inc., A Wiley Company</pub><pmid>2966931</pmid><doi>10.1002/pros.2990120203</doi><tpages>9</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0270-4137 |
| ispartof | The Prostate, 1988, Vol.12 (2), p.119-127 |
| issn | 0270-4137 1097-0045 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_78224337 |
| source | MEDLINE; Access via Wiley Online Library |
| subjects | Adult Aged Aged, 80 and over androstenedione Antineoplastic agents Biological and medical sciences Buserelin - adverse effects Buserelin - analogs & derivatives Buserelin - therapeutic use Chemotherapy dehydroepiandrosterone Delayed-Action Preparations Gonadal Steroid Hormones - blood Gonadotropin-Releasing Hormone - analogs & derivatives Goserelin Humans Male Medical sciences Middle Aged osteocalcin Pain - drug therapy Pharmacology. Drug treatments Prostatic Neoplasms - drug therapy Prostatic Neoplasms - secondary Ultrasonography |
| title | Treatment of metastatic prostate carcinoma with the depot LRH analog zoladex |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-23T20%3A00%3A57IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Treatment%20of%20metastatic%20prostate%20carcinoma%20with%20the%20depot%20LRH%20analog%20zoladex&rft.jtitle=The%20Prostate&rft.au=Holdaway,%20I.%20M.&rft.date=1988&rft.volume=12&rft.issue=2&rft.spage=119&rft.epage=127&rft.pages=119-127&rft.issn=0270-4137&rft.eissn=1097-0045&rft.coden=PRSTDS&rft_id=info:doi/10.1002/pros.2990120203&rft_dat=%3Cproquest_cross%3E78224337%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=78224337&rft_id=info:pmid/2966931&rfr_iscdi=true |